Tubing (recreation)

Fuji Electric Launches New Explosion Proof Blower

Retrieved on: 
Donnerstag, Juni 6, 2024
Technology, Hardware, Semiconductor, Consumer Electronics, Tubing (recreation), Ventilation, Multimedia, AC, SCFM, Electricity, Risk, Remedy, UL, Transport, Group C, Continuity, Blowers, Applied mechanics, Electronics, HMIS, Fuji Electric, Gas

Fuji Electric launches our new model, the EXV1000-7W 10 HP explosion proof blower.

Key Points: 
  • Fuji Electric launches our new model, the EXV1000-7W 10 HP explosion proof blower.
  • The model is a Direct Drive single stage blower with a motor defined as explosion proof: T4(T3C): Class 1, Div.1, Group C, D, with UL certificate, and equipped with a motor suitable for explosion proof requirements.
  • View the full release here: https://www.businesswire.com/news/home/20240606774118/en/
    Introducing the new EXV1000-7W 10 HP explosion-proof blower from Fuji Electric!
  • Fuji Electric Corp. of America is a wholly owned subsidiary of Fuji Electric Co., Ltd., headquartered in Tokyo, Japan and has been responsible for sales and distribution of the company’s products since 1970.

Children's Hospital of Philadelphia Study Reveals Novel Immune-Based Biomarker Helps Detect Ovarian Cancer Two to Four Years Before Conventional Diagnosis

Retrieved on: 
Freitag, Juni 14, 2024
Online, Computation, GameChanger, Patient, Immune system, Research, Protein, Doctor of Philosophy, Obstetrics, CHOP, Disease, Ovarian cancer, Biomarker, Nursing, Policy, Gynaecology, Environment, Death, Genetic distance, Hospital, NCI, Pediatrics, Nurses' Health Study, Child, Research institute, Woman, Tubing (recreation), UTSW, Life, TCR

PHILADELPHIA, June 14, 2024 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC). The findings were published today in the journal Cell Reports Medicine.

Key Points: 
  • More than 90% of women are diagnosed when the disease has reached advanced stages and has already spread, presenting significant treatment challenges.
  • Ovarian cancer is highly treatable when caught early, but tests that look for conventional biomarkers haven't been able to detect microscopic, metastatic early lesions that often develop in the fallopian tubes.
  • However, with the discovery of a novel immune-based biomarker, there is potential to change the trajectory for many women.
  • The researchers also noted that additional research is needed to aid in the development of a diagnostic test sensitive enough to detect the novel immune biomarker.

Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

Retrieved on: 
Montag, Mai 13, 2024
Medical Supplies, Women, FDA, Baby, Maternity, Fitness & Nutrition, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Patient, Oleic acid, Route of administration, Risk, Olive oil, Tubing (recreation), Parenteral nutrition, Soybean oil, Chinese, Growth, Baxter International, Malnutrition, U.S. FDA, Dietary supplement

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.
  • Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated.
  • Clinolipid has been available in the U.S. for adults since 2019 and is now available for use in all ages.
  • Over the last several years, clinical practice has shifted away from using 100 percent soybean oil lipid emulsions – which was the standard of care for decades – to mixed lipid emulsions.

Philadelphia Jury Returns $10 Million Verdict Against Albert Einstein Medical Center for Deadly Surgery

Retrieved on: 
Sonntag, Mai 12, 2024
Patient, Risk, Court of Common Pleas, Obesity, Prevalence, Einstein Medical Center Philadelphia, Hill, Tubing (recreation), Medicine, P.C, Multimedia, History, Nursing

PHILADELPHIA, May 12, 2024 /PRNewswire-PRWeb/ -- Philadelphia injury attorney Leonard Hill, founder of Hill & Associates, P.C., represented the estate of Ellen Breen, who died following a minimally invasive surgery that went wrong. Hill's colleague Susan Ayres also assisted in representing the plaintiffs.

Key Points: 
  • The jury awarded a $10 million verdict in favor of the plaintiff on February 13th.
  • The jury found that Ellen Breen's death following an operation at Albert Einstein Medical Center occurred as a result of the surgeon's negligence.
  • Defense lawyers for Albert Einstein Medical Center argued that it provided appropriate care and noted that Breen had a history of health issues and prior surgeries.
  • The case, captioned Scott v. Einstein Medical Center, was tried before Judge Craig Levin of the Philadelphia Court of Common Pleas.

Ranger Energy Services, Inc. Announces Q1 2024 Results

Retrieved on: 
Dienstag, Mai 7, 2024
Energy, Other Energy, Oil, Gas, Permian, Torrent, Tubing (recreation), Weather, Safety, Depreciation, Depression, Free cash flow, High, Ancillary services (electric power), Pressure, Acquisition, Share repurchase, Water, Growth

Ranger Energy Services, Inc. (NYSE: RNGR) (“Ranger” or the “Company”) announced today its results for the first quarter ended March 31, 2024.

Key Points: 
  • Ranger Energy Services, Inc. (NYSE: RNGR) (“Ranger” or the “Company”) announced today its results for the first quarter ended March 31, 2024.
  • Stuart Bodden, Ranger’s Chief Executive Officer, commented, “This quarter’s results presented Ranger with a unique set of challenges that adversely impacted multiple service lines.
  • As mentioned in our year-end investor call, 2024 got off to a slow start.
  • For the first quarter of 2024, revenue was $136.9 million, a decrease from $157.5 million in the prior year period.

Global Fertility Services Market Insights and Forecasts, 2020-2023, 2024 and 2025-2030 with Analyst Recommendations and Profiles of Key Players - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, April 11, 2024
Parenting, Health, Consumer, Other Health, Medication, Diagnosis, Pregnancy, Policy, Infertility, SWOT analysis, Fertility, Uterus, IVF, Tubing (recreation), Disease, ART, STI, Poverty, Reproductive technology, Movement, Research, Failure, Unsafe abortion, Da Vinci Surgical System, Endocrine system, Channel, LMIC, Genetic testing, Birth control

The "Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Female), Treatment Type, Channel, Services , By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Female), Treatment Type, Channel, Services , By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The report presents the analysis of Fertility Services Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • The report also studies the Fertility Services Market By Channel (Fertility Clinics, Hospitals, Research Institutes, and Others) and By Services (IVF, Genetic Testing, and Reproductive Tissue Storage and Donor Services).
  • Also, the attractiveness of the market has been presented by region, By Gender, By Treatment Type, By Channel, & By Services.

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Freitag, April 5, 2024
Choline, Plasma, Liver, Nutritional science, Route of administration, Liver disease, Steatosis, Short bowel syndrome, Metabolism, Patient, Choline chloride, Cancer, ESPEN, Parenteral nutrition, Adolescence, Liver injury, Hepatology, Tubing (recreation), Fibrosis, Guideline, Society, Therapy, Copenhagen University Hospital, Safety, Pharmacokinetics, PN, FDA, ASPEN, Rigshospitalet, Food, Feeding tube, Extractive metallurgy

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.

Key Points: 
  • IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
  • The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN.
  • The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.
  • “We look forward to advancing the clinical development of IV Choline Chloride, which we believe has the potential to become the first FDA approved IV choline therapy for patients dependent on PN.

Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN

Retrieved on: 
Freitag, März 29, 2024
Women, Other Communications, Baby, Maternity, Communications, Practice Management, Family, Health, Consumer, General Health, Birth, Pregnancy, Infertility, Q&A, Intrauterine device, Condom, Menstrual cycle, Sterilization, IUD, Ovulation, Research, Fertility, Pelvic inflammatory disease, Hormonal contraception, Tubing (recreation), STI, Woman, USB On-The-Go, Birth control

In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.

Key Points: 
  • In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.
  • “When choosing a birth control method, it's essential to consider factors such as efficacy, convenience, side effects, and personal preferences.
  • Dr. Kashani sheds light on various birth control methods in the following Q&A:
    What are the different types of birth control methods available?
  • There is limited evidence to suggest that using birth control methods for an extended period negatively impacts fertility.

Global Enteral Feeding Devices Market Insights 2024-2029 with Avanos Medical and B. Braun Melsungen Leading through Substantial R&D Investments - ResearchAndMarkets.com

Retrieved on: 
Dienstag, März 12, 2024
Health, Medical Devices, Other Health, Hospital, Cardiology, Incidence, Enterostomy, Neurology, Conditional sentence, Growth, Prevalence, Obesity, Esophagitis, DSM-IV codes, Patient, Research, GI, Cancer, HEN, Crohn's disease, Ageing, Parenteral nutrition, Syringe, Diet, Gastrointestinal disease, Investment, Malnutrition, Safety, IBS, Dysphagia, USD, Avanos Medical, Tubing (recreation), Pediatrics, PEG

The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.

Key Points: 
  • The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.
  • Leading firms such as Avanos Medical and B. Braun Melsungen distinguish themselves through substantial research and development (R&D) investments, forming strategic alliances, and initiatives to increase their market share.
  • The enteral feeding devices market is set for sustained growth, driven by healthcare advancements and a global emphasis on chronic disease management and nutritional support.
  • North America, particularly the United States and Canada, leads in the enteral feeding devices market.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Mittwoch, März 6, 2024
FDA, ICSI, IVF, Supreme Court of Alabama, Woman, Infertility, Female, Fertilisation, Patient, Tubing (recreation)

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.